Areas of expertise
- Infectious Diseases
- Cellular Immunology
- Medical Molecular Engineering Of Nucleic Acids And Proteins
- Cellular Interactions (Incl. Adhesion, Matrix, Cell Wall)
- Medical Virology
Funding 2010 - 2016
Past and Current Funding
- NH&MRC Project grant
- 2 x NH&MRC Development grants
- Bill & Melinda Gates Foundation, Grand Challenge Exploration Phase I
- 5 Australian Centre for HIV & Hepatitis Virology Research grants
- 3 x Gordon and Gretel Bootes Foundation awards.
- Commercial funding
- 2 DTF grants
- Ranasinghe C, Turner SJ, McArthur C et al. (2007) Mucosal HIV-1 pox virus prime-boost immunization Induces high-avidity CD8+ T cells with regime-dependent cytokine/granzyme B profiles. J Immunol. 178(4), 2370-2379.
- Ranasinghe C, Trivedi S, Stambas J, Jackson RJ (2013) Unique IL-13Ralpha2-based HIV-1 vaccine strategy to enhance mucosal immunity, CD8(+) T-cell avidity and protective immunity. Mucosal Immunol 6: 1068-1080.
Jackson RJ, Worley M, Trivedi S, Ranasinghe C (2014) Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy. Vaccine Vaccine 32: 5703–5714.
- Ranasinghe C, Trivedi S, Wijesundara DK, Jackson RJ: IL-4 and IL-13 receptors: Roles in immunity and powerful vaccine adjuvants. Cytokine Growth Factor Rev 23(14), 00072-00070 (2014).
- Trivedi S, Jackson RJ, Ranasinghe C (2014). Different HIV pox viral vector-based vaccines and adjuvants can induce unique antigen presenting cells that modulate CD8 T cell avidity. Virology 468-470C, 479-489.